Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Prieto

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2012
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaPeter A Prieto, James C Yang, Richard M Sherry, et al.
Plastic and Reconstructive Surgery|May 23, 2023
Wise Pattern versus Transverse Pattern Mastectomy in Two-Stage Implant-Based Breast Reconstruction: A Propensity Score-Matched AnalysisJoseph M Escandón, James A Butterfield, Jose G Christiano, et al.
Journal of Cancer|May 5, 2012
Liver directed therapy for renal cell carcinomaRussell C Langan, R Taylor Ripley, Jeremy L Davis, et al.
Cancers|June 2, 2021
Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma ModelShuyang S Qin, Booyeon J Han, Alyssa Williams, et al.
Immunological Investigations|June 6, 2020
Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal AdenocarcinomaBooyeon J Han, Joseph D Murphy, Shuyang Qin, et al.
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Cell Reports|October 10, 2019
Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune MicroenvironmentBradley N Mills, Kelli A Connolly, Jian Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2010
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanomaMark E Dudley, Colin A Gross, Michelle M Langhan, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2012
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaPeter A Prieto, James C Yang, Richard M Sherry, et al.
Plastic and Reconstructive Surgery|May 23, 2023
Wise Pattern versus Transverse Pattern Mastectomy in Two-Stage Implant-Based Breast Reconstruction: A Propensity Score-Matched AnalysisJoseph M Escandón, James A Butterfield, Jose G Christiano, et al.
Journal of Cancer|May 5, 2012
Liver directed therapy for renal cell carcinomaRussell C Langan, R Taylor Ripley, Jeremy L Davis, et al.
Cancers|June 2, 2021
Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma ModelShuyang S Qin, Booyeon J Han, Alyssa Williams, et al.
Immunological Investigations|June 6, 2020
Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal AdenocarcinomaBooyeon J Han, Joseph D Murphy, Shuyang Qin, et al.
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Cell Reports|October 10, 2019
Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune MicroenvironmentBradley N Mills, Kelli A Connolly, Jian Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2010
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanomaMark E Dudley, Colin A Gross, Michelle M Langhan, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Pageof 5